285 related articles for article (PubMed ID: 9707499)
1. The roles of CYP3A and CYP2B isoforms in hepatic bioactivation and detoxification of the pyrrolizidine alkaloid senecionine in sheep and hamsters.
Huan JY; Miranda CL; Buhler DR; Cheeke PR
Toxicol Appl Pharmacol; 1998 Aug; 151(2):229-35. PubMed ID: 9707499
[TBL] [Abstract][Full Text] [Related]
2. The effect of spironolactone treatment on the cytochrome P450-mediated metabolism of the pyrrolizidine alkaloid senecionine by hepatic microsomes from rats and guinea pigs.
Chung WG; Buhler DR
Toxicol Appl Pharmacol; 1994 Aug; 127(2):314-9. PubMed ID: 8048076
[TBL] [Abstract][Full Text] [Related]
3. Human liver microsomal reduction of pyrrolizidine alkaloid N-oxides to form the corresponding carcinogenic parent alkaloid.
Wang YP; Yan J; Fu PP; Chou MW
Toxicol Lett; 2005 Mar; 155(3):411-20. PubMed ID: 15649625
[TBL] [Abstract][Full Text] [Related]
4. Bioactivation and detoxication of the pyrrolizidine alkaloid senecionine by cytochrome P-450 enzymes in rat liver.
Williams DE; Reed RL; Kedzierski B; Dannan GA; Guengerich FP; Buhler DR
Drug Metab Dispos; 1989; 17(4):387-92. PubMed ID: 2571477
[TBL] [Abstract][Full Text] [Related]
5. Species differences in the hepatic microsomal enzyme metabolism of the pyrrolizidine alkaloids.
Huan JY; Miranda CL; Buhler DR; Cheeke PR
Toxicol Lett; 1998 Oct; 99(2):127-37. PubMed ID: 9817084
[TBL] [Abstract][Full Text] [Related]
6. Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid senecionine in human liver.
Miranda CL; Reed RL; Guengerich FP; Buhler DR
Carcinogenesis; 1991 Mar; 12(3):515-9. PubMed ID: 2009596
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of phencyclidine by human liver microsomes.
Laurenzana EM; Owens SM
Drug Metab Dispos; 1997 May; 25(5):557-63. PubMed ID: 9152594
[TBL] [Abstract][Full Text] [Related]
8. Comparison of hepatic in vitro metabolism of the pyrrolizidine alkaloid senecionine in sheep and cattle.
Duringer JM; Buhler DR; Craig AM
Am J Vet Res; 2004 Nov; 65(11):1563-72. PubMed ID: 15566096
[TBL] [Abstract][Full Text] [Related]
9. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
10. In vitro complex formation and inhibition of hepatic cytochrome P450 activity by different macrolides and tiamulin in goats and cattle.
Zweers-Zeilmaker WM; Van Miert AS; Horbach GJ; Witkamp RF
Res Vet Sci; 1999 Feb; 66(1):51-5. PubMed ID: 10088712
[TBL] [Abstract][Full Text] [Related]
11. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions.
Fabre G; Julian B; Saint-Aubert B; Joyeux H; Berger Y
Drug Metab Dispos; 1993; 21(6):978-85. PubMed ID: 7905403
[TBL] [Abstract][Full Text] [Related]
12. Major factors for the susceptibility of guinea pig to the pyrrolizidine alkaloid jacobine.
Chung WG; Buhler DR
Drug Metab Dispos; 1995 Nov; 23(11):1263-7. PubMed ID: 8591728
[TBL] [Abstract][Full Text] [Related]
13. A cytochrome P4502B form is the major bioactivation enzyme for the pyrrolizidine alkaloid senecionine in guinea pig.
Chung WG; Miranda CL; Buhler DR
Xenobiotica; 1995 Sep; 25(9):929-39. PubMed ID: 8553686
[TBL] [Abstract][Full Text] [Related]
14. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
Danie WA; Syrek M; Ryłko Z; Wójcikowski J
Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
[TBL] [Abstract][Full Text] [Related]
15. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe.
Chauret N; Tremblay N; Lackman RL; Gauthier JY; Silva JM; Marois J; Yergey JA; Nicoll-Griffith DA
Anal Biochem; 1999 Dec; 276(2):215-26. PubMed ID: 10603245
[TBL] [Abstract][Full Text] [Related]
16. [Involvement of cytochrome P4503A in the monohydroxylation of ring A of praziquantel in rat liver microsomes].
Zhang YJ; Quan YZ
Yao Xue Xue Bao; 1997; 32(1):5-10. PubMed ID: 11243219
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Ma B; Prueksaritanont T; Lin JH
Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
[TBL] [Abstract][Full Text] [Related]
18. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
19. CYP2C and CYP2B Mediated Metabolic Activation of Retrorsine in Cyp3a Knockout Mice.
Pang X; Tang C; Kong F; Chen M; Chen X
Curr Drug Metab; 2020; 21(13):1040-1051. PubMed ID: 33267758
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
